CME: Mining the Outer Reaches of Migraine Science

Mining the Outer Reaches of Migraine Science

Mining the Outer Reaches of Migraine Science

These advances in treatment are offering hope for the more than 36 million Americans living with migraine.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    What do discoveries in migraine science mean for its treatment? Explore how established therapies and targeted medicines are chipping away at the frequency and severity of recalcitrant migraine in an update led by expert faculty: Dr. Wade Cooper and host Dr. Jennifer Caudle.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    1. Describe MOAs of new therapeutics as acting on pathophysiologically determined targets.
    2. Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine.
  • Target Audience

    The target audiences are headache specialists and PCPs. Other healthcare professionals, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with migraine may benefit from participation.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planner (Forefront Collaborative): Sydney Pate, MS
    • Presenter (ReachMD): Jennifer Caudle, DO

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    • Planner: Shirley Kessel has participated in a speaker’s bureau for Valeant; She has participated in an advisory board for Allergan Minds Project.
    • Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
    • Presenter: Wade Cooper, DO has consulted for and has ownership interest in Dolor Technologies; Dr. Cooper has participated in an advisory board for Promius.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

    Credit Designation Statement
    Forefront Collaborative designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative. 

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit 

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

  • CME Content Review

    The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free